Mumbai, Jan. 22 -- The revenue growth was broad-based across key markets, except for North America Generics which reported a decline primarily on account of lower Lenalidomide sales. Growth was further aided by favourable foreign exchange rate movements.

Profit before tax (PBT) dropped 17.68% YoY to Rs 1,542.9 crore during the quarter.

EBITDA stood at Rs 2,049.3 crore, registering de-growth of 12.84% compared with Rs 2351.1 crore posted in corresponding quarter last year. EBITDA margin reduced to 23.5% in Q3 FY26 as against 26.7% in Q3 FY25.

Revenue from global generics increased 7% YoY to Rs 7,911.3 crore during the quarter.

In Q3 FY26, revenue from North America declined 20% YoY to Rs 2,964.4 crore, primarily due to lower Lenalidomi...